Generic name:tafasitamab [ TA-fa-SIT-a-mab ]
Drug class:CD19 monoclonal antibodies
What is Monjuvi?
Monjuvi is an antibody that targets the CD19 antigen.
Monjuvi is used in combination with lenalidomide to treat diffuse large B-cell lymphoma in adults who cannot receive a stem cell transplant.
Monjuvi is given after other cancer treatments did not work or have stopped working.
Monjuvi was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to this medicine, but further studies are needed.
Warnings
Monjuvi affects your immune system. You may get infections more easily, even serious or fatal infections. Call your doctor if you have signs of infection (fever, cough with mucus, chest tightness, shortness of breath, or pain or burning when you urinate).
Monjuvi may harm an unborn baby. Use effective birth control to prevent pregnancy while using Monjuvi and for at least 3 months after your last dose.
Carefully follow all instructions about the use of birth control while you are using Monjuvi in combination with lenalidomide.
Before taking this medicine
Tell your doctor if you have any signs of infection, or if you have recently had an infection.
Tafasitamab may harm an unborn baby. Use effective birth control to prevent pregnancy while using this medicine and for at least 3 months after your last dose. Tell your doctor if you become pregnant.
Monjuvi is sometimes used in combination with lenalidomide. Both men and women using lenalidomide must use effective birth control. Even one dose can cause severe, life-threatening birth defects or death of a baby if...
